Coles, Alasdair

Multiple sclerosis

Compston, A., & Coles, A. (2002) · The Lancet

Multiple Sclerosis Research StudiesPsoriasis: Treatment and Pathogenesis

Cited by 1,743

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Cohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., et al. (2012) · The Lancet

Multiple Sclerosis Research StudiesChronic Lymphocytic Leukemia Research

Cited by 1,205

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Coles, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., et al. (2012) · The Lancet

Multiple Sclerosis Research StudiesChronic Lymphocytic Leukemia Research

Cited by 1,198

Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis

Coles, A. J., Wing, M., Smith, S., Coraddu, F., Greer, S., Taylor, C., Weetman, A., Hale, G., Chatterjee, V. K., Waldmann, H., et al. (1999) · The Lancet

Multiple Sclerosis Research StudiesT-cell and B-cell Immunology

Cited by 453

Mutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans

Schoenmakers, E., Agostini, M., Mitchell, C., Schoenmakers, N., Papp, L., Rajanayagam, O., Padidela, R., Ceron-Gutierrez, L., Doffinger, R., Prevosto, C., et al. (2010) · Journal of Clinical Investigation

Selenium in Biological SystemsOrganoselenium and organotellurium chemistry

Cited by 315

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings

Coles, A. J., Cohen, J. A., Fox, E. J., Giovannoni, G., Hartung, H.-P., Havrdova, E., Schippling, S., Selmaj, K. W., Traboulsee, A., Compston, D. A. S., et al. (2017) · Neurology

Multiple Sclerosis Research StudiesPolyomavirus and related diseases

Cited by 277

Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy

Tuohy, O., Costelloe, L., Hill-Cawthorne, G., Bjornson, I., Harding, K., Robertson, N., May, K., Button, T., Azzopardi, L., Kousin-Ezewu, O., et al. (2015) · Journal of Neurology, Neurosurgery & Psychiatry

Multiple Sclerosis Research StudiesPolyomavirus and related diseases

Cited by 238

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy

Havrdova, E., Arnold, D. L., Cohen, J. A., Hartung, H.-P., Fox, E. J., Giovannoni, G., Schippling, S., Selmaj, K. W., Traboulsee, A., Compston, D. A. S., et al. (2017) · Neurology

Multiple Sclerosis Research StudiesPolyomavirus and related diseases

Cited by 221

Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort

Cossburn, M., Pace, A. A., Jones, J., Ali, R., Ingram, G., Baker, K., Hirst, C., Zajicek, J., Scolding, N., Boggild, M., et al. (2011) · Neurology

Multiple Sclerosis Research StudiesAutoimmune Neurological Disorders and Treatments

Cited by 216

Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features

Pariani, N., Willis, M., Muller, I., Healy, S., Nasser, T., McGowan, A., Lyons, G., Jones, J., Chatterjee, K., Dayan, C., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism

Thyroid Disorders and TreatmentsOphthalmology and Eye Disorders

Cited by 84